Centrum Medyczne Med-Gastr Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Centrum Medyczne Med‑Gastr is conducting studies aimed at reducing the burden of heart‑related conditions. Trials evaluate new therapies to prevent recurrent acute myocardial infarction, lower risk in patients with atrial fibrillation, and improve outcomes for those at risk of atherosclerotic cardiovascular disease. The focus is on testing innovative agents that may cut major adverse cardiovascular events and provide safer anticoagulation options.
- Evaluation of novel lipid‑lowering compounds for primary prevention
- Assessment of anticoagulant alternatives in atrial fibrillation
- Combination therapy for diabetes‑related cardiovascular risk
- Self‑administered treatment for suspected acute myocardial infarction
With 29 active trials and 11 investigators, the Łódź site contributes to advancing cardiovascular care across Europe.
Digestive System Diseases
Research at the centre targets inflammatory and immune‑mediated disorders of the gut. Ongoing studies assess the effectiveness of novel biologics for inducing remission in Crohn’s disease and ulcerative colitis, as well as therapies aimed at reducing eosinophilic inflammation in eosinophilic esophagitis and eosinophilic gastritis. Additional work explores dietary‑based interventions for celiac disease.
- Induction and maintenance therapies for moderate to severe IBD
- Targeted treatment of fistulizing perianal Crohn’s disease
- Histologic improvement in eosinophilic gastrointestinal disorders
- Gluten challenge mitigation strategies in celiac disease
The site’s multidisciplinary team is engaged in 29 trials, offering patients access to cutting‑edge gastrointestinal research.
Immune System Diseases
The facility’s immune‑system portfolio includes trials that modulate abnormal immune responses. Studies investigate targeted antibodies to achieve clinical remission in moderate to severe immune system diseases, evaluate long‑term safety of immune‑modulating agents, and explore histologic improvement in eosinophilic gastrointestinal conditions.
- Novel monoclonal antibodies for ulcerative colitis
- Safety monitoring of long‑term immune‑modulators
- Combination strategies for eosinophilic esophagitis
- Biomarker‑driven approaches to personalize therapy
Centrum Medyczne Med‑Gastr’s investigators bring expertise from 11 clinicians to support these immune‑focused programs.
Nutritional and Metabolic Diseases
Metabolic health is addressed through trials that aim to manage weight, glucose, and blood pressure. Research evaluates the impact of new agents on reducing obesity, improving control of type 2 diabetes, and lowering hypertension while also assessing cardiovascular safety.
- Weight‑loss therapies with cardiovascular outcome assessment
- Combination glucose‑lowering and antihypertensive regimens
- Prevention of major adverse cardiovascular events in diabetic patients
- Metabolic risk reduction strategies in overweight populations
The Łódź clinic’s commitment to metabolic disease research aligns with its broader goal of preventing cardiovascular complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Med-Gastr Sp. z o.o.
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Subjects with Chronic Kidney Disease-associated Pruritus (CKD-aP) | Mc2 Therapeutics Limited | Phase II | Not Recruiting | Feb 2023 | Feb 2024 |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 4 | Unknown | 2026-03-02 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.